Introduction: 68Ga-DOTATOC PET/CT is a reference method for imaging somatostatin receptor (sstr) expressing neuroendocrine tumors (NET). Presence and extent of liver metastases impact on patient management and prognosis.
Aim(s): To investigate safety and diagnostic accuracy of 68Ga-OPS202, a radiolabelled sstr antagonist for PET/CT imaging of gastroenteropancreatic (GEP) NET (ClinicalTrials.gov NCT02162446).
Materials and methods: Twelve metastatic G1/G2 GEP-NET patients were enrolled in a prospective phase 1/2 imaging study to investigate two single doses of 68Ga-OPS202 (A: 15μg & B: 50μg) in comparison with 68Ga-DOTATOC PET/CT. Scans were reviewed by 2 independent blinded readers. Follow-up imaging and biopsy were used as standard of reference.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Guillaume Nicolas
, Schreiter N
, Kaul F
, Uiters J
, Mena R
, Bauman A
, Bouterfa H
, Reubi J C
, Rivier J
, Maecke H
, Cathomas R
, Christ E
, Fani M
, Wild D
To read results and conclusion, please login ...
Further abstracts you may be interested in
Introduction: The majority of patients diagnosed with gastroenteropancreatic (GEP)-NETs present metastases expressing somatostatin receptor 2 (SSTR2). The 68Gallium-labelled SSTR2 antagonist 68Ga-OPS202 has shown improved diagnostic performance as a PET imaging agent compared with the SSTR2 agonist 68Ga-DOTA-TOC in a single-centre study.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Irene Virgolini
Introduction: Patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) present frequently with hepatic metastases. Radiofrequency ablation (RFA) is an important local ablative treatment for hepatic metastases.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Prof. Dr. Richard P Baum
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: Dr Daniel Kaemmerer
Introduction: PRRT with radiolabelled SSTR agonists is highly effective and has become an integral part of NET treatment. Tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. DOTA-JR11 (OPS201) is a very promising next-generation SSTR2-selective antagonist.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Guillaume Nicolas
Introduction: Grade 2 GEP-NETs have inherent tumor heterogeneity seen with positive expression of somatostatin (SSTR) and glucose (GLUT) receptors. Prior surgical resection and imaging parameters on Ga-68 DOTANOC PET/C are well-established variable impacting prognosis in well-differentiated grade 1 NETs. Since the degree of differentiation is variable in Grade 2 NETs, these parameters have not been studied.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Ameya Puranik